Prizloncabtagene autoleucel clinical trials
How each study uses prizloncabtagene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the prizloncabtagene autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2020 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 6
First Affiliated Hospital of Zhejiang University (1) · Peking University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Peking Union Medical College Hospital (1) · Shanghai Tongji Hospital, Tongji University School of Medicine (1) · AbelZeta Inc. (1) · Shanghai AbelZeta Ltd. (1) · Canyon City Eyecare (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test prizloncabtagene autoleucel.
- Mar 2027A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell LymphomaPhase 1/2 · Shanghai AbelZeta Ltd.
Studies
Open first, then newest update. How each study uses prizloncabtagene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyNot yet recruitingPhase 2AbelZeta Inc.NCT07875413Written as Prizloncabtagene Autoleucel
- A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell LymphomaRecruitingPhase 1/2Shanghai AbelZeta Ltd.NCT05800977Written as Prizloncabtagene autoleucel
- A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's LymphomaCompletedPhase 1Peking UniversityNCT05149391Written as CD19/CD20-directed Chimeric Antigen Receptor T Cells
- A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedPhase 1Tianjin Medical University Cancer Institute and HospitalNCT04696432Written as Prizloncabtagene autoleucel
- A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedPhase 1Peking Union Medical College HospitalNCT04655677Written as Prizloncabtagene Autoleucel
- A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL SubjectsCompletedPhase 1Shanghai Tongji Hospital, Tongji University School of MedicineNCT04317885Written as Prizloncabtagene Autoleucel
- A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's LymphomaActive, not recruitingPhase 1First Affiliated Hospital of Zhejiang UniversityNCT04693676Written as Prizloncabtagene Autoleucel
- A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or HyperopiaStatus unknownPhase 1/2Canyon City EyecareNCT04883996Written as 1% EXP039
Codes
What other systems call prizloncabtagene autoleucel · ClinicalTrials.gg INT014592
- UNII (FDA) 35X9XB2HBGPRIZLONCABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C178452Prizloncabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 35X9XB2HBG | PRIZLONCABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C178452 | Prizloncabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.